Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
YM BioSciences CIMYM BioSciences |
---|---|
Information provided by: | YM BioSciences |
ClinicalTrials.gov Identifier: | NCT00369447 |
This is a Phase I-II study designed to investigate nimotuzumab (TheraCIM h-R3) in combination with external radiation in patients with non-small cell lung cancer. The purpose of the Phase I portion of the study is to evaluate the safety and feasibility of the administration of nimotuzumab with palliative radiation in patients who are unsuitable for radical therapy and to select the optimal dose for the Phase II component of the study.
The primary objective for the Phase II portion of the study is to examine the efficacy of this combination treatment.
The Phase I component of this study has been completed. The Phase II is now open for recruitment.
Condition | Intervention | Phase |
---|---|---|
Non-Small-Cell Lung Cancer |
Procedure: External radiotherapy Biological: nimotuzumab |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination With External Radiotherapy in Stage IIB, III and IV NSCLC |
Estimated Enrollment: | 128 |
Study Start Date: | March 2009 |
Estimated Study Completion Date: | March 2011 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
200 mg dose
|
Procedure: External radiotherapy
Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
Biological: nimotuzumab
weekly dose until disease progression
|
2: Placebo Comparator |
Procedure: External radiotherapy
Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
Biological: nimotuzumab
weekly dose until disease progression
|
This is a randomized, double blind, multicenter Phase II study with Phase I lead-in. Patients enrolled in this study will receive external radiotherapy with or without nimotuzumab (TheraCIM h-R3). The objective of the Phase I component of the study is to evaluate the safety and feasibility of the administration of nimotuzumab with palliative radiation in patients who are unsuitable for radical therapy (curative intent chemoradiation) and to select the optimal biologically effective dose (BED) for Phase II component of the study. In the Phase II component, overall survival, local and systemic response rates and quality of life will be evaluated inpatients treated with nimotuzumab in combination with palliative radiation vs. radiation alone.
The Phase I component of this study has been completed. The Phase II is now open for recruitment.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Exclusion criteria - Phase I and Phase II:
Contact: Leonardo Viana, MD | 905 629 9761 |
Canada, Alberta | |
Tom Baker Cancer Center | Recruiting |
Calgary, Alberta, Canada | |
Canada, Ontario | |
Princess Margaret Hospital | Not yet recruiting |
Toronto, Ontario, Canada |
Principal Investigator: | Gwyn Bebb, MD | Tom Baker Cancer Center |
Principal Investigator: | Anthony Brade, MD | Princess Margaret Hospital, Canada |
Responsible Party: | YM BioSciences ( Director, Clinical Research ) |
Study ID Numbers: | YMB1000-010 |
Study First Received: | August 24, 2006 |
Last Updated: | April 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00369447 History of Changes |
Health Authority: | Canada: Health Canada; Canada: Ethics Review Committee |
Non small cell lung cancer NSCLC Nimotuzumab TheraCIM |
h-R3 YM BioSciences Radiation Non small cell lung cancer, Stage IIb, III and IV |
Thoracic Neoplasms Respiratory Tract Diseases Lung Neoplasms Lung Diseases |
Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |